Interview Summary	Application No.	Applicant(s)	
	09/183,375	SZEBENI ET AL.	
	Examiner	Art Unit	
	Gollamudi S. Kishore, Ph.D	1615	
All participants (applicant, applicant's representative, PTO personnel):			
(1) Gollamudi S. Kishore, Ph.D.	(3) <u>Dr. Janos Szebein</u> .		
(2) <u>Thomas G. Wiseman</u> .	(4) <u>Dr. Alving</u> .		
Date of Interview: 20 December 2007.			
Type: a)☐ Telephonic b)☐ Video Conference c)☐ Personal [copy given to: 1)☐ applicant 2)☒ applicant's representative]			
Exhibit shown or demonstration conducted: d) Yes e) No. If Yes, brief description:			
Claim(s) discussed: <u>claims on record</u> .			
Identification of prior art discussed: <i>Prior art on record</i> .			
Agreement with respect to the claims f) was reached. g) was not reached. h) N/A.			
Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: <u>See Continuation Sheet</u> .			
(A fuller description, if necessary, and a copy of the amendments which the examiner agreed would render the claims allowable, if available, must be attached. Also, where no copy of the amendments that would render the claims allowable is available, a summary thereof must be attached.)			
THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN A NON-EXTENDABLE PERIOD OF THE LONGER OF ONE MONTH OR THIRTY DAYS FROM THIS INTERVIEW DATE, OR THE MAILING DATE OF THIS INTERVIEW SUMMARY FORM, WHICHEVER IS LATER, TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW. See Summary of Record of Interview requirements on reverse side or on attached sheet.			
	45	li S. Kishore, PhD	
	Gollamud Primary I Group 1 5	Examiner	
Examiner Note: You must sign this form unless it is an Attachment to a signed Office action.	Examiner's sig	nature, if required	

Continuation of Substance of Interview including description of the general nature of what was agreed to if an agreement was reached, or any other comments: Dr. Szebeni descrirbed the compliment activation system and how the hypersensitivity is caused by polyethoxylated oils and how the claimed inhibitors inbibit the hypersensitivity. The following were suggested. Claims to define that the hypersensitivity reaction is by compliment activation; delete the compounds claimed by generic termrs (last 3 lines of claim 1). Since the application is under final, a continuation will be filed. Applicant possibly will conduct additional experiments for the antibodies specific for compliment activation..

Golfamudi S. Kishore, PhL

Primary Examiner

Group 1600